Medimmune Limited

Genzyme Corporation

Optein, Inc.

Cambridge Antibody Technology Limited

Lutz Jermutus

Ralph Raymond Minter

Steven R Ledbetter

Robert G Holgate

Alexander R Duncan

Celia Patricia Hart

Donna K Finch

Catriona L Buchanan

Melissa Marie Damschroder

Scott A Hammond

Sandrine Guillard

Ching Ching Leow

Carl Hay

Li Cheng

Jonathan Rios-Doria

Mary Antonysamy

Xiaojun Lu

Roland Bürli

Maria Herva

Andrew Grier Buchanan

Steven Rust

Peter Pavlik

Robert E Hollingsworth

Phillip David Monk

Kris Sachsenmeier

Celia Patricia Shorrock

Erin Sult

Nicholas Durham

Qihui Huang

Gundo Diedrich

Steve Rust

James Geoghegan

Kim Rosenthal

Damian C Crowther

Albert George Thom

Maria Aleksandra Bednarek

Jonathan P Hatcher

Carl Innes Webster

Philip Ambery

Marcella Petrone

Andrew Buchanan

Philip David Monk

Celia P Hart

In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.

Conjugates for targeting and clearing aggregates

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Binding molecules specific for CD73 and uses thereof

The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF&#x3b2;), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF&#x3b2;1, TGF&#x3b2;2 and TGF&#x3b2;3, so-called 'pan-specific' antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).

Antibodies to TGF-&#x3b2;

Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonists peptides.

Glucagon and GLP-1 co-agonists for the treatment of obesity

The disclosure provides transporter molecules capable of carrying agents of interest across the blood brain barrier. Also provided are polynucleotides encoding transporter molecules, methods making transporter molecules, and methods of using transporter molecules, e.g., for the diagnosis, prevention, or treatment of central nervous system diseases, disorders, or injuries.

Blood brain barrier transport molecules and uses thereof

The present invention relates to antibody molecules, in particular antibody molecules that bind. Transforming Growth Factor beta (TGF&#x3b2;), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF&#x3b2;1, TGF&#x3b2;2 and TGF&#x3b2;3, so-called 'pan-specific' antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).

Antibodies to TGF-beta

Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Human antibody molecules for IL-13

The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF&#x3b2;), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF&#x3b2;1, TGF&#x3b2;2 and TGF&#x3b2;3, so-called 'pan-specific' antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).

Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Methods of treatment using human antibody molecules for IL-13

Growing community of inventors

Cambridge, United Kingdom

Lutz Jermutus